A Study on the Safety and Efficacy of Riliprubart in Participants with Chronic Inflammatory Demyelinating Polyneuropathy Who Are Not Responding to Standard Treatments
Summary description of the study
The aim of this study is to find out whether a new medication called Riliprubart works in people with CIDP whose condition has not improved under standard treatments. The study will also ensure that Riliprubart is safe for the individuals receiving it.
(BASEC)
Intervention under investigation
This study investigates Riliprubart. It is a type of medication that prevents a specific part of the body's immune system from being overly active. A placebo (dummy medication) will also be used in the study. The placebo looks like the medication being studied – however, it contains no active ingredient. Therefore, it is also called a 'dummy medication.' In the first part of the study, it will be determined how well Riliprubart improves disability compared to a placebo treatment. In the second part, it will be assessed how well Riliprubart works to improve disability in the long term.
(BASEC)
Disease under investigation
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare condition in which the body's immune system attacks the myelin that surrounds and protects the nerves. People with CIDP typically suffer from muscle weakness, making it difficult for them to walk. They may also experience strange sensations such as tingling, numbness, or coordination difficulties. This often leads to increasing disability, which may require physical therapy, special devices like braces, or even a wheelchair.
(BASEC)
I 02. The participant must have CIDP or possible CIDP criteria. I 03. The participant must be refractory (non-responsive) to either immunoglobulin therapy or corticosteroid therapy. I 05. All permitted immunosuppressants (azathioprine, ciclosporin, or mycophenolate mofetil) must have been taken at a stable dose for ≥6 months before screening. I 06. The participant may receive low-dose oral corticosteroids, but only if they have been taken at a stable dose for ≥3 months before screening. I 08. The participant must have documented vaccinations against encapsulated bacterial pathogens [Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae] within 5 years prior to screening or have the vaccinations initiated at least 14 days before the first dose of the investigational product. (BASEC)
Exclusion criteria
E 01. Polyneuropathy of other causes. E 03. Any other neurological or systemic disease that may cause symptoms and signs that could interfere with treatment or outcome assessment. E 04. Poorly controlled diabetes (HbA1c > 7%). E 05. Severe infections. E 12. The participant has received immunoglobulins (IVIg or SCIg) within 8 weeks prior to screening. E 13. Treatment with plasma exchange within 8 weeks prior to screening. (BASEC)
Trial sites
Bern
(BASEC)
Sponsor
Sanofi-aventis (suisse) sa 3, Route de Montfleury 1214 Vernier
(BASEC)
Contact
Contact Person Switzerland
Hanka Klaus
+49 (0)30 2575 2442
CSU-CTA-EK@cluttersanofi.comSanofi-aventis (suisse) sa 3, Route de Montfleury 1214 Vernier
(BASEC)
Scientific Information
not available
Name of the authorising ethics committee (for multicentre studies, only the lead committee)
Ethics Committee Bern
(BASEC)
Date of authorisation
27.08.2024
(BASEC)
ICTRP Trial ID
not available
Official title (approved by ethics committee)
A Phase 3, double-blind, placebo-controlled study evaluating efficacy and safety of riliprubart in participants with refractory chronic inflammatory demyelinating polyneuropathy (BASEC)
Academic title
not available
Public title
not available
Disease under investigation
not available
Intervention under investigation
not available
Type of trial
not available
Trial design
not available
Inclusion/Exclusion criteria
not available
not available
Primary and secondary end points
not available
not available
Registration date
not available
Incorporation of the first participant
not available
Secondary sponsors
not available
Additional contacts
not available
Secondary trial IDs
not available
Results-Individual Participant Data (IPD)
not available
Further information on the trial
not available
Results of the trial
Results summary
not available
Link to the results in the primary register
not available